Q-omics provides the consensus-scored B3GALT6 profile across patient tissues and cancer cell-line models. B3GALT6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, B3GALT6 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, B3GALT6 RNA expression shows 18,351 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where B3GALT6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B3GALT6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B3GALT6 survival associations across molecular data types. B3GALT6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B3GALT6 RNA expression–survival associations across cancer types. High B3GALT6 expression shows unfavorable associations in ACC, BLCA, LIHC and COAD, but favorable associations in THYM and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for B3GALT6 RNA expression.
This table summarizes B3GALT6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for B3GALT6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B3GALT6 shows higher tumor expression in HNSC, COAD, KIRC, LIHC, STAD and BLCA. The HNSC box plot shows higher B3GALT6 RNA expression in tumor versus normal tissue (log2 FC = +0.801, t-test p < 0.001).
This table shows molecular features associated with B3GALT6 in patient tissues and cancer cell lines. In patient samples, B3GALT6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, B3GALT6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
